Cargando…
Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab
Thrombotic microangiopathies (TMAs) include thrombotic thromobocytopenic purpura and hemolytic uremic syndrome (HUS). Among these conditions, atypical HUS is now recognized to be a disease of alternative complement pathway dysregulation. Eculizumab is a recombinant humanized monoclonal antibody that...
Autores principales: | Jin, Anna, Boroujerdi-Rad, Laleh, Shah, Gaurang, Chen, Joline L.T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957717/ https://www.ncbi.nlm.nih.gov/pubmed/27478600 http://dx.doi.org/10.1093/ckj/sfw035 |
Ejemplares similares
-
Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
por: Allinovi, Marco, et al.
Publicado: (2017) -
An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy
por: Aigner, Christof, et al.
Publicado: (2019) -
Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone
por: Nataatmadja, Melissa, et al.
Publicado: (2016) -
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea
por: Brocklebank, Vicky, et al.
Publicado: (2017) -
Pneumococcal hemolytic uremic syndrome and steroid resistant nephrotic syndrome
por: Groves, Andrew P., et al.
Publicado: (2016)